Evaluation Of Visual Outcomes After Implantation Of An Extended Depth-Of-Focus Intraocular Lens In Patients With Mild Glaucoma.
Published 2024 - 42nd Congress of the ESCRS
Reference: PP02.11 | Type: Free paper | DOI: 10.82333/nsfx-vf39
Authors: Gorka Lauzirika* 1 , Javier Aritz Urcola 1 , Igor Illarramendi 1 , Andrea Soto Velasco 2 , Ronald M. Sánchez-Ávila 3 , Carlota Fuente-García 3 , Aitor Fernández-García 3
1Miranza Begitek,Donostia - San Sebastián,Spain, 2Miranza Okular,Vitoria - Gasteiz,Spain, 3Miranza IOA,Madrid,Spain
Purpose
To describe the visual, refractive, functional and patients’ satisfaction outcomes of the AcrySof™ IQ Vivity™ EDOF IOL in patients with mild primary open angle glaucoma (POAG).
Setting
Miranza Begitek (Plaza Teresa Calcuta 7. 20012, Donostia – San Sebastián, Spain).
Methods
This was an ambispective, noninterventional, descriptive, cross-sectional study. Patients with mild (Hodapp-Parrish-Anderson classification), stable POAG for at least 6 months, and AcrySof™ IQ Vivity™ EDOF IOL were included. The Humphrey Field Analyzer III campimeter (Carl Zeiss Meditec, Dublin, CA, USA) and Triton optical coherence tomography (Topcon, Japan) were used to evaluate the inclusion criteria. Refractive outcomes and visual acuity at distance, intermediate, and near were evaluated from 3 months post-operatively onwards. Also, binocular contrast sensitivity (CSV-1000, VectorVision), binocular defocus curve, and patient satisfaction with IOLSAT and QUVID questionnaires were assessed.
Results
72 AcrySof™ IQ Vivity™ from 36 patients were enrolled. The mean thickness of RNFL was 75.73±16.03 µm, the mean IOP was 16.22±3.39 mmHg, and the active principles as topic treatment was 0.79±0.94. CDVA, DCIVA, DCNVA were 0.09±0.13, 0.14±0.13 and 0.24±0.11 LogMAR respectively. The binocular defocus curve shows a peak of visual acuity at 0 D of 0.00±0.10 LogMAR; 0.12±0.10 LogMAR at -1.5D and 0.35±0.17 LogMAR at -2.5D. Binocular contrast sensitivity shows a decrease in high spatial frequencies. The IOLSat reveals that in bright light conditions, 96.97%, 100%, and 69.70% of patients “Never” or “Rarely” need glasses at far, arm’s length, and near distances respectively; and according to the QUVID, 97.06% of patients report no shadow areas.
Conclusions
The new AcrySof™ IQ Vivity™ EDOF IOL seems to provide good visual outcomes at distance, intermediate, and near vision, with an adequate contrast sensitivity and defocus curve and a low rate of visual disturbances in patients with mild and stable POAG.